A Case Crossover Study of Intermittent Fasting in CLL/SLL

Plain-language summary

This study examined the effect of intermittent fasting approaches in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It enrolled people under 85 with these diagnoses who met certain blood-count criteria, evaluating the 5:2 and 16/8 fasting methods. It was a trial without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

British Columbia Cancer Agency

Intervention

5:2 Method (intermittent fasting regimen), 16/8 Method (intermittent fast regimen)

Start date

6/12/2023

Estimated completion

12/30/2023

Countries

Canada

Related genes

Locations

• Victoria, Canada

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Diagnosis of CLL or SLL
* Age \< 85 years
* Peripheral blood lymphocytes \>20 x 109/L
* Hemoglobin \> 90g/L
* Platelets \> 90 x 10\*9/L
* BMI of \>=20kg/m2
* ECOG Performance Status \>=2
* Completion of "IF in CLL/SLL Study" (ClinicalTrials.gov Identifier: NCT04626843) followed by minimum of 3 month ad libitum eating

Exclusion Criteria:

* Patient unable to give consent
* Patient on medications required to be taken with food during the fasting window
* Pregnancy
* Diabetes mellitus
* BMI drop to \< 18.5kg/m2 at any time during study
* Anti-lymphoma therapy within the past 3 months
* Expected to require initiation of anti-lymphoma therapy within the next 3 months